Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
Business Wire•16/11/2026•07:00 ET
1
Key Highlights
- ➤Turn Therapeutics (TTRX) to present GX-03 Phase 2b plans at Jefferies conference
- ➤GX-03 Phase 2a results informed an optimized atopic dermatitis Phase 2b design
- ➤Presentation scheduled November 16, 2026, in London
Expert Statements
Bradley Burnam, Chief Executive Officer of Turn Therapeutics
“Over our first year as a Nasdaq-listed company, we reported encouraging Phase 2a results, published two peer-reviewed studies, and assembled an incredible team of clinical and scientific leaders, including former FDA Commissioner Dr. Stephen Hahn and former CDC Director Dr. Robert Redfield”
Bradley Burnam, Chief Executive Officer of Turn Therapeutics
“We used what we learned in Phase 2a to optimize the design of Phase 2b. We are honored to present at Jefferies and share our plans for advancing GX-03 into 2027.”
Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will deliver a company presentation as part of the Jefferies Global Healthcare Conference in London. Presentation details are as follows:
Get started
Create a free account to read the full story.
